Loading...
Docoh

Pacific Biosciences of California (PACB)

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Tuesday
14 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 951 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
13 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Monday's trading, 1214 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
10 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 422 stocks made new 52-week lows.
Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
16 May 22
Analyst Ratings
Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.
Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $6
16 May 22
News, Price Target, Analyst Ratings
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $13 to $6.
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $14
6 May 22
News, Price Target, Analyst Ratings
Morgan Stanley maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $15 to $14.
Pacific Biosciences Clocks 14% Jump In Q1 Revenues
5 May 22
Earnings, News, Guidance, Health Care, Small Cap, General
Recap: Pacific Biosciences Q1 Earnings
4 May 22
Earnings
Pacific Biosciences (NASDAQ:PACB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Pacific Biosciences Q1 EPS $(0.37) Misses $(0.31) Estimate, Sales $33.20M Beat $32.82M Estimate
4 May 22
Earnings, News
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 17.78 percent increase over losses of $(0.45) per share
Earnings Scheduled For May 4, 2022
4 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
20 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 160 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
15 Apr 22
M&A, News, Small Cap, Top Stories
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Press releases

From Benzinga Pro
PacBio Grants Equity Incentive Award to New Employee
27 Jun 22
Press Releases
MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
14 Jun 22
News, Management, Press Releases
CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
5 May 22
News, Press Releases
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio's management is
PacBio Announces First Quarter 2022 Financial Results
4 May 22
Earnings, Press Releases
MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase
PacBio and Children's Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease
21 Apr 22
Health Care, Press Releases
MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children's
PacBio transforms access to the epigenome and streamlines workflows
21 Apr 22
Health Care, Press Releases
MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to
PacBio to Report First Quarter 2022 Financial Results on May 4, 2022
20 Apr 22
News, Press Releases
MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022,
This Little Known Cancer Play has been Crushing the Market (ADGI, OTLC, DVAX, PACB, SAVA, NVAX, IMGN, BNTX)
14 Apr 22
News, Press Releases
Volatility remains the dominant factor across the equities market, with interest rates rising and growth stocks well underwater so far in 2022. Ground zero for this correction is among “long duration